Re: Emmeli Palmstedt, Marianne Månsson, Jonas Hugosson, Rebecka Arnsrud Godtman. Active Surveillance for Screen-detected Low- and Intermediate-risk Prostate Cancer: Extended Follow-up up to 25 Years in the GOTEBORG-1 Trial. Eur Urol. 2025;88:373-380.

Ginsburg KB; Zamani A; Borza T

doi:10.1016/j.eururo.2025.07.029

← 뒤로

Re: Emmeli Palmstedt, Marianne Månsson, Jonas Hugosson, Rebecka Arnsrud Godtman. Active Surveillance for Screen-detected Low- and Intermediate-risk Prostate Cancer: Extended Follow-up up to 25 Years in the GOTEBORG-1 Trial. Eur Urol. 2025;88:373-380.

European urology 2025 Vol.88(6) p. e122-e123

Ginsburg KB, Zamani A, Borza T

원문 ↗ DOI ↗ BibTeX ↓ RIS ↓

이 논문을 인용하기

BibTeX ↓ RIS ↓

APA Ginsburg KB, Zamani A, Borza T (2025). Re: Emmeli Palmstedt, Marianne Månsson, Jonas Hugosson, Rebecka Arnsrud Godtman. Active Surveillance for Screen-detected Low- and Intermediate-risk Prostate Cancer: Extended Follow-up up to 25 Years in the GOTEBORG-1 Trial. Eur Urol. 2025;88:373-380.. European urology, 88(6), e122-e123. https://doi.org/10.1016/j.eururo.2025.07.029

MLA Ginsburg KB, et al.. "Re: Emmeli Palmstedt, Marianne Månsson, Jonas Hugosson, Rebecka Arnsrud Godtman. Active Surveillance for Screen-detected Low- and Intermediate-risk Prostate Cancer: Extended Follow-up up to 25 Years in the GOTEBORG-1 Trial. Eur Urol. 2025;88:373-380.." European urology, vol. 88, no. 6, 2025, pp. e122-e123.

PMID 40998627

DOI 10.1016/j.eururo.2025.07.029

같은 제1저자의 인용 많은 논문 (1)

Factors associated with switching from active surveillance to treatment in men with low-risk prostate cancer: A population-based study.
Cancer 2025